Updated National Cholesterol Guidelines Released by Medical Experts

On March 13, 2026, the American College of Cardiology and the American Heart Association—joined by nine other medical societies—published the most sweeping revision of U.S. cholesterol management guidelines in eight years. The 2026 Guideline on the Management of Dyslipidemia replaces the 2018 blood cholesterol guideline and introduces changes that will reshape how physicians assess cardiovascular risk, whom they treat, and how aggressively they pursue lower lipid levels [1][2].

The core message: start screening earlier, treat to specific numerical targets, and use a broader toolkit of biomarkers and medications than ever before. But the guideline has also triggered a sharp professional debate over evidence quality, industry influence, and whether American medicine is once again expanding the definition of disease to the benefit of pharmaceutical manufacturers.

What Changed: The Numbers

The most consequential shift is the return of explicit LDL cholesterol targets—a practice the ACC/AHA abandoned in 2013 when it moved to a "treat the risk, not the number" philosophy. That era is over [3].

Under the new framework, treatment goals are stratified by cardiovascular risk:

• Primary prevention, borderline or intermediate risk: LDL-C below 100 mg/dL [1]
• Primary prevention, high risk: LDL-C below 70 mg/dL [1]
• Secondary prevention, high-risk ASCVD: LDL-C below 70 mg/dL; non-HDL-C below 100 mg/dL [3]
• Secondary prevention, very high-risk ASCVD: LDL-C below 55 mg/dL; non-HDL-C below 85 mg/dL [3]
• Coronary artery calcium (CAC) score ≥1,000: LDL-C below 55 mg/dL [3]

For context, the 2018 guideline did not set specific LDL targets. Instead, it recommended percentage reductions—50% or more for high-risk patients on high-intensity statins—without specifying a destination number [6]. The new approach aligns the U.S. more closely with European practice, which has used numerical targets for years [7].

The guideline also establishes a new threshold for considering medication in younger adults: anyone 30 or older with LDL-C at or above 160 mg/dL, a strong family history of premature cardiovascular disease, or elevated 30-year risk on the PREVENT calculator should discuss statin therapy with their physician [2][4]. Previously, routine risk-based assessment started at age 40.

A New Risk Calculator and Expanded Testing

Gone are the Pooled Cohort Equations that formed the backbone of cardiovascular risk assessment for nearly two decades. The guideline now recommends the PREVENT (Predicting Risk of Cardiovascular Disease EVENTs) calculator for adults ages 30 to 79 without known atherosclerotic cardiovascular disease (ASCVD) [1][3].

PREVENT estimates both 10-year and 30-year risk of heart attack or stroke and incorporates variables including body mass index, cholesterol levels, and tobacco use. The 10-year risk categories are: low (below 3%), borderline (3% to under 5%), intermediate (5% to under 10%), and high (10% or higher) [4].

The shift to PREVENT created an internal tension during the guideline's development. As STAT News reported, the new equations would have reduced statin eligibility by as much as 40% if paired with the old treatment thresholds—because PREVENT produces lower risk estimates than the Pooled Cohort Equations, which overestimated 10-year risk by 40% to 50% [4]. The writing committee resolved this by pairing the new calculator with lower treatment thresholds and longer time horizons.

Three new biomarker recommendations stand out:

• Lipoprotein(a): A one-time blood test recommended for all adults, ideally in early adulthood. Lp(a) is genetically determined and stable over a lifetime; elevated levels signal inherited risk for heart attacks and strokes. An estimated 64 million Americans carry elevated Lp(a) [5][9].
• Apolipoprotein B (apoB): Recommended to assess residual risk in patients with cardiovascular-kidney-metabolic syndrome, Type 2 diabetes, high triglycerides, or established cardiovascular disease who have already reached their LDL-C and non-HDL-C goals [1].
• Coronary artery calcium (CAC) scoring: Recommended selectively for men over 40 and women over 45 with borderline or intermediate risk [9].

Source: GDELT Project

Data as of Mar 28, 2026CSV

The Clinical Evidence Behind the Changes

Several major trials published since the 2018 guideline informed the revision. The CLEAR Outcomes trial—a randomized study of 13,970 statin-intolerant patients—demonstrated that bempedoic acid reduced major adverse cardiovascular events by 13% relative to placebo (11.7% vs. 13.3%; hazard ratio 0.87; p = 0.004), while lowering LDL-C by 21% [10][11]. This gave the committee confidence to include bempedoic acid as a recommended add-on therapy.

The VESALIUS-CV trial provided evidence that evolocumab, a PCSK9 inhibitor, reduced coronary heart disease deaths, myocardial infarction, and stroke, achieving LDL levels around 45 mg/dL [3].

However, the evidence base is uneven. An analysis by Dr. James Stein, a cardiologist and lipidologist, found that only about 20% of the guideline's Class 1 (strongest) recommendations rest on Level of Evidence A—meaning high-quality randomized controlled trial data. Roughly one-third rely on Level B-R (moderate randomized evidence), and approximately 40% carry Level B-NR, meaning "supporting data come entirely from nonrandomized or observational studies" [12]. Nearly half of the guideline's top-tier recommendations lack any randomized trial evidence base.

Notably, inclisiran—a twice-yearly injectable that lowers LDL-C by silencing the PCSK9 gene—still lacks cardiovascular outcomes data. The ORION-4 and VICTORION-2P outcome trials are expected to conclude in 2026 and 2027 [11].

How Many Americans Are Affected?

Approximately one in four U.S. adults—roughly 86 million people—have elevated LDL cholesterol [5][9]. The guideline does not provide a single estimate of how many additional patients will newly qualify for statin therapy, but several factors point to a substantial expansion:

• Lowering the risk assessment starting age from 40 to 30 brings an additional decade of adults into formal screening [4].
• Reinstating specific LDL targets means patients who previously met percentage-reduction goals may now fall short of the new numerical benchmarks.
• Universal Lp(a) screening will identify an estimated 64 million Americans with a previously undetected genetic risk factor [5].
• The 30-year risk horizon captures younger adults whose 10-year risk appears low but whose cumulative lifetime exposure to elevated lipids is substantial.

Dr. Steven Nissen of the Cleveland Clinic called the lifetime risk focus "a sea change" and predicted substantial increases in statin prescriptions [5].

The U.S. vs. the World: International Comparisons

The 2026 U.S. guidelines bring American practice closer to the European Society of Cardiology and European Atherosclerosis Society (ESC/EAS) approach, which has used numerical LDL targets since 2019. The ESC/EAS 2019 guidelines—updated in 2025—recommend LDL-C below 55 mg/dL for very high-risk patients and below 70 mg/dL for high-risk patients, with an additional requirement of at least 50% reduction from baseline [7][8].

A key philosophical difference persists. The ESC/EAS guidelines have been more aggressive in recommending non-statin add-on therapies—ezetimibe, PCSK9 inhibitors—across broader patient groups when targets are not met. The 2018 ACC/AHA guidelines were more conservative, reserving non-statin agents for select populations [7]. The 2026 revision narrows this gap but does not eliminate it entirely.

A simulation study using real-world data from the DA VINCI study found that simulated 10-year cardiovascular risk was lower when patients achieved 2019 ESC/EAS goals (25%) versus the 2018 ACC/AHA approach (28%), suggesting the target-based European model produced somewhat better modeled outcomes [7].

The Committee and Industry Ties

The writing committee comprised 33 members chaired by Dr. Roger Blumenthal of Johns Hopkins University and co-chaired by Dr. Pamela Morris of the Medical University of South Carolina. Both the chair and vice-chair disclosed no relevant industry relationships [1][12].

But the rest of the committee tells a different story. Of the remaining 31 writing committee members, approximately half disclosed relevant relationships with pharmaceutical manufacturers, imaging companies, digital health companies, or genetic testing companies—often with multiple companies simultaneously [12]. Dr. Ann Marie Navar, for instance, reported relationships with Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bayer, Eli Lilly, Esperion, Johnson & Johnson, Merck, NewAmsterdam Pharma, Novartis, Novo Nordisk, Sanofi, and Silence Therapeutics [13].

Over two-thirds of the 29-member peer review committee—the body intended to provide independent assessment of the writing committee's conclusions—also disclosed relevant industry conflicts of interest [12].

The ACC/AHA conflict-of-interest policy requires committee members to recuse themselves from voting on sections to which their specific relationships may apply [13]. Whether this firewall is sufficient is a matter of ongoing debate in cardiology. A 2017 BMJ analysis of earlier cholesterol guidelines found that 44% of committee members disclosed commercial conflicts, with all disclosing industry-sponsored research [14].

What It Will Cost

The cost picture varies dramatically depending on the prescribed therapy.

Generic statins—atorvastatin, rosuvastatin, simvastatin—now cost approximately $3 per month, making them among the least expensive prescription medications available [5]. Generic ezetimibe, a common add-on, is similarly affordable.

The expense escalates with newer agents. PCSK9 inhibitors (evolocumab and alirocumab) carried original list prices exceeding $14,000 annually, though manufacturers reduced prices by roughly 60% to approximately $5,850 per year [15]. Even after reductions, Medicare Part D beneficiaries have faced cost-sharing requirements exceeding $300 per month, and nearly one-third of patients abandoned their PCSK9 prescriptions at the pharmacy because of cost [15].

Bempedoic acid (Nexletol), now incorporated into the guideline as a recommended non-statin option, carries a list price of roughly $4,600 per year.

The guideline's expansion of treatment eligibility will increase aggregate healthcare spending, though the magnitude depends on how many newly eligible patients are prescribed generic statins (minimal cost impact) versus branded non-statin therapies (substantial cost impact). No official cost-impact estimate has been published with the guideline.

The Number That Matters Most: Who Actually Benefits?

For patients already at high cardiovascular risk, statins provide substantial, well-documented benefit. In the JUPITER trial, the five-year number needed to treat (NNT) to prevent one major cardiovascular event was 20 among people with low LDL but elevated inflammatory markers [16].

For lower-risk populations—the group most expanded by these guidelines—the calculus is less favorable. Data from TheNNT.com, a physician-run evidence resource, and published meta-analyses indicate that for patients at low cardiovascular risk, the five-year NNT to prevent a nonfatal heart attack is approximately 217, and the NNT to prevent a nonfatal stroke is approximately 313 [16][17]. No statistically significant reduction in overall mortality has been demonstrated in low-risk primary prevention populations [17].

On the harm side, treatment of 10,000 patients for five years with standard statin therapy is associated with approximately 5 cases of myopathy (NNH ~2,000) and 50 to 100 new cases of Type 2 diabetes [18]. A 2024 Lancet meta-analysis found that low-to-moderate intensity statin therapy increased new-onset diabetes by 10%, while high-intensity therapy increased it by 36% [18]. Muscle pain (myalgia) occurs in roughly 5% of statin users compared to placebo, yielding an NNH of approximately 21 [18].

These numbers frame the central policy question: for a 35-year-old with an LDL of 165 mg/dL and no other risk factors, is decades of statin therapy justified by the modest absolute risk reduction, given the side-effect profile?

The Lifestyle-First Critique

Not all physicians welcome the expansion. Critics argue the guidelines risk over-medicalizing otherwise healthy individuals while underinvesting in behavioral interventions.

The guideline states that healthy lifestyle habits—diet, exercise, tobacco avoidance, healthy sleep—are "foundational" to cardiovascular prevention [1]. But as critics have observed, this language often serves as a brief preamble before detailed pharmacotherapy algorithms. Published case evidence demonstrates that lifestyle changes alone can reduce LDL cholesterol by more than 50% in motivated individuals—comparable to moderate-intensity statin therapy [19].

Dr. Stein's critique of the 2026 guideline focused on its expansion of testing protocols. "A guideline that responds to uncertainty by adding more testing—more imaging, more genetic panels, more biomarkers—backed by observational data...does not serve patients. It serves the ecosystem," he wrote [12]. His concern centers on the cascade effect: each new test generates findings that trigger further tests and treatments, often without randomized evidence that the cascade improves outcomes.

The structural critique runs deeper. Because randomized controlled trials are expensive and nearly exclusively funded by pharmaceutical companies, the evidence base for drug therapy is inherently larger and more robust than for lifestyle interventions, which lack a commercial sponsor [20]. This creates a systematic tilt in evidence-based guidelines toward pharmacotherapy—not because drugs are necessarily superior, but because the evidence infrastructure is built to study them.

A 2025 health-economic evaluation published in PLOS ONE found that lifestyle changes could achieve cholesterol targets set by guidelines at lower cost and with fewer adverse effects than statin therapy for patients at moderate cardiovascular risk [19].

The guideline's defenders counter that lifestyle recommendations have been part of every iteration of cholesterol guidelines for decades, and adherence remains poor. Dr. Blumenthal emphasized that "80% or more of cardiovascular disease is preventable" through lifestyle modification, but argued that biomarkers and medications are necessary for the substantial population that does not achieve adequate risk reduction through behavior change alone [5].

What Comes Next

The 2026 dyslipidemia guideline will shape clinical practice for millions of Americans over the coming years. Its emphasis on earlier screening, numerical targets, and expanded biomarker testing represents a clear philosophical shift toward more aggressive, earlier intervention.

Whether that shift will produce the anticipated reduction in cardiovascular events depends on several open questions: Will the newly eligible populations actually fill prescriptions and take them consistently? Will insurers cover the expanded testing recommended by the guideline? Will the pending outcomes trials for inclisiran and other newer agents validate the committee's forward-leaning recommendations? And will primary care physicians—who manage the vast majority of cholesterol patients—have the time and resources to implement a substantially more complex risk assessment protocol?

The answers will emerge not from the guideline document itself, but from the messy reality of clinical practice, insurance formularies, and patient preferences. For now, one thing is clear: the bar for what constitutes acceptable cholesterol has dropped, and the age at which Americans are expected to start worrying about it has dropped with it.